Fermenta Biotech Limited (FERMENTA) has announced its consolidated financial results for the half year ended September 30, 2026 (H1FY27). The company reported consolidated revenue of INR 261.9 crore, a 7% year-on-year decline. The EBITDA and profit after tax for the period were INR 45.6 crore and INR 18.9 crore respectively, down 34% and 52% year-on-year.

Revenue Breakdown

The revenue for the period was primarily driven by the Human Nutrition segment, which now accounts for close to two-thirds of the total revenue. The Vitamin D3 – Human Nutrition business saw a 2% growth despite a 13% year-on-year decline in volumes. The Vitamin D3 – Animal Nutrition segment experienced a significant drop, with volumes down 31% and average realization down 35% year-on-year.

Geographical Revenue Shift

India has emerged as the largest market for FERMENTA, contributing 51% of the consolidated revenue in H1FY27, up from 40% a year earlier. This shift underscores the company’s strategic focus on steadier markets while navigating the price cycle in animal nutrition.

Forward-Looking Statements

Prashant Nagre, Managing Director of Fermenta Biotech Limited, emphasized the company’s balanced approach, highlighting the FSSAI approval for VITADEE Green® and the expected readiness of Calcifediol by the end of FY27. He also noted the benefits of the company’s listing on the National Stock Exchange (NSE), which has broadened investor access.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Fermenta Biotech Limited

Fermenta Biotech Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Fermenta rises 12.3% over three months, with buying pressure holding steady. Revenue grows at 14.5% CAGR. The company generates cash but does not compound aggressively. The stock holds at 38% of its 52-week range with RSI at 43. In other words, neither side has a clear edge right now. Revenue grows at 14.5% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Fermenta Biotech Limited.

Shilpa Medicare Limited (SHILPAMED) has announced record earnings for the 2nd quarter and the first half of FY27, marking a significant milestone for the company. The financial results highlight robust growth across all business segments, driven by strategic initiatives and strong market demand.

Financial Highlights

In the 2nd quarter of FY27, Shilpa Medicare Limited reported its highest-ever quarterly revenue of INR 538 crores, marking a 45% year-over-year (YoY) growth. The earnings before interest, taxes, depreciation, and amortization (EBITDA) also reached a new high at INR 151 crores, up 37% YoY. The profit after tax (PAT) surged to INR 79 crores, an 80% increase from the previous year.

Full-Year First Half Performance

For the first half of FY27, the company’s total income crossed the INR 1,000 crore mark for the first time, growing 44% YoY to INR 1,007 crores. The EBITDA grew 40% YoY to INR 290 crores, maintaining a stable margin of 29%. The PAT nearly doubled to INR 180 crores, with the PAT margin expanding to 18%.

Strategic Focus and Future Outlook

The company’s focus on innovation-led differentiation has paid off, evidenced by high-value partnerships such as the expanded collaboration with Orion Corporation for the development and supply of Nivolumab biosimilar in Europe. With a maturing pipeline and a sharpened strategic focus, Shilpa Medicare Limited is well-positioned to deliver stronger performance for the remainder of FY27.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Shilpa Medicare Limited

Shilpa Medicare Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Shilpa gains 51.2% over three months and trades near its 52-week highs. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. No meaningful dividend — total return is entirely dependent on capital appreciation. Buyers show up with 1.5x the volume of sellers. Moreover, they dominated on 16 of recent sessions versus 14 for sellers — a healthy accumulation pattern. The stock rises 51.2% in three months on 13.8% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Shilpa Medicare Limited.

Hester Biosciences Limited (HESTERBIO) has announced securing an unsecured loan of USD 1 million from itself to its wholly-owned subsidiary, Hester Biosciences Africa Limited. The loan, which is to be disbursed in one or more tranches, carries an interest rate of 9% per annum and a tenure of three years from the first draw down. The loan will be utilized for business and general corporate purposes, including working capital requirements, as permitted under applicable laws. Notably, the transaction falls under related party transactions as per SEBI regulations but is exempted under Regulation 23(5)(b) due to the nature of the relationship between the holding company and its wholly-owned subsidiary. The loan agreement is expected to be executed by 15 November 2026, and as of the date of this announcement, no amount has been drawn.

Financial Overview

The financial health of Hester Biosciences Limited remains robust, with a significant increase in revenue from operations for the quarter ended 30 September 2026. The company reported a revenue of INR 1,555.88 million, a notable improvement from INR 1,280.69 million in the same period last year. Profit before tax also saw a substantial rise, reaching INR 420.91 million compared to INR 201.70 million in the previous year. The company’s earnings per share (EPS) stood at INR 36.88, reflecting strong financial performance.

Future Outlook

With this strategic financial maneuver, Hester Biosciences Limited is well-positioned to bolster its operational capabilities and expand its market presence. The company remains committed to its growth trajectory and is poised to leverage this financial resource to achieve its long-term business objectives.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Hester Biosciences Limited

Hester Biosciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Hester falls 8.6% over three months and has not found a floor yet. The PEG of 0.50 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. Industry-leading margins of 41.6% reflect exceptional pricing power and operational efficiency. The stock gains 1.3% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Both the business and the stock move in the right direction. Revenue grows at 7.7%, profits at 27.8%, and the PEG sits at 0.50 — below its growth rate. That combination is rare. Check Fundamentals of Hester Biosciences Limited.